Systemic Therapy of HR-positive, HER2-negative metastatic Breast Cancer

被引：0
作者：
Lorenz, Judith
机构：
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2022年 / 82卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：257 / 257
页数：1
相关论文
共 50 条
[41]   Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer [J].
Burstein, Harold J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26) :2557-2570
[42]   Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer [J].
Burstein, Harold J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12) :1176-1177
[43]   Using baseline MRI radiomics to predict the tumor shrinkage patterns in HR-Positive, HER2-Negative Breast Cancer [J].
Wang, Lijia ;
Wang, Yongchen ;
Yang, Li ;
Ren, Jialiang ;
Xu, Qian ;
Zhai, Yingmin ;
Zhou, Tao .
FRONTIERS IN ONCOLOGY, 2025, 15
[44]   Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer [J].
Ferro, Antonella ;
Campora, Michela ;
Caldara, Alessia ;
De Lisi, Delia ;
Lorenzi, Martina ;
Monteverdi, Sara ;
Mihai, Raluca ;
Bisio, Alessandra ;
Dipasquale, Mariachiara ;
Caffo, Orazio ;
Ciribilli, Yari .
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (12)
[45]   Efficacy of fulvestrant-based therapies in treating HR-positive, HER2-negative breast cancer with liver metastasis [J].
Chien, Christine ;
Madak-Erdogan, Zeynep ;
Goel, Mahima ;
Gangidi, Suma ;
Tripathy, Debu ;
Raghavendra, Akshara Singareeka .
CANCER RESEARCH, 2023, 83 (05)
[46]   HR-positive, HER2-negative Breast Cancer Prolongation of Survival by the CDK4 & 6 Inhibitor Abemaciclib [J].
Schmale, Ine .
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (12) :690-691
[47]   Impact of PET and PET/CT Radiotracer for Evaluating Efficacy of CDK4/6 Inhibitor Therapy in HR-Positive HER2-Negative Metastatic Breast Cancer [J].
Imamovic, Elma ;
Veledar, Anisa ;
Kalic, Zerina ;
Softic, Adna ;
Mrdanovic, Emina ;
Smajlhodzic-Deljo, Merima .
MEDICON 2023 AND CMBEBIH 2023, VOL 1, 2024, 93 :345-350
[48]   Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer [J].
Le, Vivian ;
Zhong, Lixian ;
Narsipur, NihaL ;
Hays, Elizabeth ;
Tran, Daniel Khuong ;
Rosario, Kimberly ;
Wilson, Leslie .
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (03) :327-338
[49]   ASCO 2019-Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC [J].
Beslija, Semir .
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (04) :305-307
[50]   A real-world experience of palbociclib-induced adverse events in women with HR-positive/Her2-negative metastatic breast cancer. [J].
Watson, Geoffrey Alan ;
Deac, Oana ;
Aslam, Razia ;
O'Dwyer, Richard ;
Sukor, Sue ;
Kennedy, Michael John .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345